Manoj Sadhnani, DPM
Foot & Ankle Surgery · Rosedale, NYNPI 1164521191
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Integra Lifesciences Corporation at 47.5% of the total. Reporting peaked in 2019 at $16,234 and has fallen 87.8% since, to $1,976 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $143.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$17K
- Royal Biologics, Inc.$4K
- Gotham Surgical Solutions & Devices, Inc.$3K
- Stryker$3K
- Smith+Nephew$2K
- Polaris Technology Solutions LLC$2K
- plus $5K from 17 others
What the payments were for
- Consulting fees$3,0319%
- Speaking & faculty fees$12,06635%
- Travel & lodging$3,49410%
- Food & beverage$11,83734%
- Education$4,32012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 65 | $16,506 |
| Royal Biologics, Inc. | 4 | $3,688 |
| Gotham Surgical Solutions & Devices, Inc. | 4 | $3,154 |
| Stryker(2 entities) | 28 | $2,626 |
| Smith+Nephew | 63 | $2,282 |
| Polaris Technology Solutions LLC | 5 | $1,930 |
| Next Science LLC | 18 | $954 |
| Treace Medical Concepts, Inc. | 9 | $541 |
| Kerecis Limited | 2 | $540 |
| Paratek Pharmaceuticals, Inc. | 13 | $503 |
| Arthrex | 4 | $471 |
| Acera Surgical, Inc. | 3 | $363 |
| AbbVie(2 entities) | 8 | $220 |
| Davol Inc. | 4 | $190 |
| Globus Medical | 2 | $184 |
| DJO, LLC | 2 | $162 |
| Averitas Pharma Inc. | 1 | $105 |
| Bioventus LLC | 1 | $101 |
| In2bones USA, LLC | 1 | $84 |
| Accufix Surgical Inc. | 1 | $70 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Orthofix Medical, Inc. | 1 | $15 |
| Lifenet Health | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SALTO TALARIS TOTAL ANKLE PROSTHESIS$14,878
- PANTA NAIL$12,093
- TOTAL FOOT SYSTEM$12,093
- CADENCE ANKLE REPLACEMENT SYSTEM$12,093
- Fibrinet$3,652
- MaxxCell$3,652
- AmnioMaxx$3,500
- PANTA 2 ARTHRODESIS NAIL SYSTEM$2,784
- HALLU-LOCK$1,612
- INTEGRA$1,127
- GRAFIX PL$1,059
- Kerecis Omega3 Marigen$750
- SurgX$676
- Xperience$676
- BlastX$676
- PRIMATRIX$506
- INTEGRA DERMAL REGENERATION TEMPLATE$506
- CITREFIX$441
- Actishield$418
- AUGMENT INJECTABLE$384
How this compares
$34,748 in reported general payments places this provider in the 90th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 47 | $40,159 |
| Doxepin Hcl | 42 | $3,875 |
| Fluocinonide | 23 | $1,551 |
| Diclofenac Sodium ErDiclofenac Sodium | 14 | $1,085 |
| Clotrimazole | 11 | $625 |
| Doxycycline Hyclate | 34 | $249 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $174 |
| Cefadroxil | 21 | $79 |
| Ibuprofen | 16 | $67 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $53 |
| Meloxicam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $2,282 | $40,15947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 foot & ankle surgery providers in New York.
Other foot & ankle surgery in Rosedale
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$597K
- John KennedyNew York$534K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$328K
- Stuart MogulNew York$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.